MBX Biosciences, Inc. (NASDAQ:MBX – Get Free Report) CEO Steven Hoerter sold 4,893 shares of MBX Biosciences stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $54.82, for a total value of $268,234.26. Following the transaction, the chief executive officer owned 78,045 shares in the company, valued at $4,278,426.90. This represents a 5.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
MBX Biosciences Price Performance
NASDAQ:MBX opened at $54.51 on Friday. The business’s fifty day moving average price is $55.89 and its 200 day moving average price is $46.29. MBX Biosciences, Inc. has a 1-year low of $23.07 and a 1-year high of $72.64.
MBX Biosciences (NASDAQ:MBX – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.49). Analysts predict that MBX Biosciences, Inc. will post -3.20 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Institutional Investors Weigh In On MBX Biosciences
Large investors have recently bought and sold shares of the business. State of Wyoming bought a new stake in shares of MBX Biosciences during the 2nd quarter worth $58,000. Sterling Capital Management LLC grew its stake in MBX Biosciences by 847.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,033 shares of the company’s stock valued at $61,000 after buying an additional 924 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in MBX Biosciences in the 3rd quarter valued at $144,000. Quantbot Technologies LP bought a new position in MBX Biosciences in the 2nd quarter worth $213,000. Finally, Sei Investments Co. raised its holdings in MBX Biosciences by 17.4% in the 1st quarter. Sei Investments Co. now owns 8,989 shares of the company’s stock worth $268,000 after acquiring an additional 1,332 shares during the period.
MBX Biosciences Company Profile
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for endocrine and metabolic disorders. The company’s research focuses on conditions in which naturally occurring hormones are deficient or do not function adequately. MBX uses its Precision Endocrine Peptide (PEP) platform to design peptide medicines intended to provide more durable hormone activity. Its lead candidate, MBX 2109, is being developed as a long-acting parathyroid hormone replacement therapy for people with chronic hypoparathyroidism.
Featured Articles
- Five stocks we like better than MBX Biosciences
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
